Freenome uses multiomics platform for cancer detection
The platform combines genomics, proteomics, and transcriptomics with AI to identify cancer patterns.
See the latest news and media coverage for Freenome. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotech company developing blood tests for early cancer detection
freenome.comLast updated
In short: Freenome reached a $330 million SPAC deal to go public and secured inclusion in the updated ACS colorectal cancer screening guideline.
The platform combines genomics, proteomics, and transcriptomics with AI to identify cancer patterns.
The ACS updated its screening guideline to include blood-based tests like SimpleScreen, aiming to increase screening participation.
One poster shows consistent CRC test performance across age groups, and another finds blood-based testing cost-effective for incomplete colonoscopy programs.
The posters focus on multiomics platform and early cancer detection efforts.
Perceptive Capital Solutions Corp ("PCSC") (Nasdaq: PCSC), a special purpose acquisition company ("SPAC") sponsored by an affiliate of Perceptive Advisors, and Freenome Holdings, Inc. ("Freenome...
/PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, welcomes the inclusion of blood-based testing in the...
/PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, today announced initial development data for its...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Track Freenome and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Freenome and other trending companies.